



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



INFORMATION REQUIRED U/S 160 AND 168 OF THE COMPANIES ACT, 2013 READ WITH RULE 13 AND RULE 15 OF THE COMPANIES (APPOINTMENT AND QUALIFICATIONS OF DIRECTORS) RULES, 2014

&

Disclosure under Regulation 30(8) of SEBI (LODR) 2015

SR. NO	NAME OF EVENT	EFFECTIVE DATE
1	Resignation of Mr. Bhikhabhai Chimanlal Shah	08/04/2015
2	Resignation of Mr. Kaushal Kamlesh Shah	05/01/2017
3	Resignation of Mr. Rajendra Rambhai Patel	05/01/2017
4	Appointment of Mr. Kirit Nanubhai Shelat as an Independent Director of the Company	03/02/2017
5	Appointment of Mrs. Vijaya Sampath as an Independent Director of the Company	03/02/2017
6	Appointment of Mr. Rajiv Gulati as an Independent Director of the Company	03/02/2017
7	Appointment of Mr. Shardul Suresh Shroff as an Independent Director of the Company	03/02/2017
8	Resignation of Mr. Sanjiv Kaul	26/05/2017
8	Resignation of Mr. Rajiv Gulati	06/10/2017
9	Resignation of Mr. Shardul Suresh Shroff	01/02/2018
10	Appointment of Mr. Prashant Gupta as an additional Independent Director of the Company	30/04/2018
11	Resignation of Mr. Himanshu Shah	30/09/2019

Last Updated on 03/07/2019

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer
Membership No.: A26493

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013



Date: July 3, 2019

The Manager
Dept. of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Script Code: 540596

The Asst Vice President
Listing Department
National Stock Exchange of India
Limited
Exchange Plaza, C-1, Block G
Bandra – Kurla Complex,
Mumbai 400051
Symbol: ERIS

Dear Sir,

Sub: Outcome of the meeting of the Board of Directors of Eris Lifesciences Limited (Company) held today, i.e. on July 3, 2019

Pursuant to Regulation 30 of the Listing Regulations and other applicable provisions of law, we wish to inform you that, the Board of Directors of the Company at its meeting held today, i.e. July 3, 2019 has inter-alia:

1. Approved buyback proposal for purchase by the Company of its own fully paid equity shares of Re. 1 each (Equity Share) up to 17,39,130 Equity Shares (being ~1.26% of the total paid-up equity capital of the Company) at a price of Rs. 575/- (Rupees Five hundred seventy five only) per Equity Share, for a maximum aggregate consideration not exceeding Rs. 100 crore (Rupees One hundred crore Only) [excluding any expenses incurred or to be incurred for the Buyback like filing fees payable to the Securities and Exchange Board of India, if any, brokerage, applicable taxes (such as securities transaction tax, stamp duty and goods and service tax), advisors' fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses], being less than 25% of the aggregate paid-up equity share capital and free reserves (including securities premium account) of the Company as on March 31, 2019 (hereinafter referred to as the Buyback) from the shareholders of the Company on a proportionate basis through the tender offer route in accordance and consonance with the provisions contained in the Companies Act, 2013 and the Securities and Exchange Board of India (Buy Back of Securities) Regulations, 2018 (Buyback Regulation) (including any statutory modification(s) or re-enactment of the Companies Act, 2013 or Buyback Regulation). The public announcement setting out the process, timelines and other statutory details will be released in due course in accordance with the Buyback Regulation. The Board has designated the Executive Committee to act as Buyback and Executive Committee (the "Buyback Committee / Committee") and has delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback. The pre-Buyback shareholding pattern of the Company as on June 28, 2019 is attached hereto as Annexure A and the post Buy-Back shareholding pattern and actual securities bought back (in number and percentage) of the existing paid up capital will be provided on completion of the Buy-Back.

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013



2. Noted that the Promoters and Promoter Group of the Company have expressed their intention to not participate in the Buyback.

3. Fixed Monday, July 15, 2019 as the Record Date for the purpose of determining the entitlement and the names of equity shareholders who are eligible to participate in the Buyback.

4. Extended the relieving date of Mr. Himanshu Shah as Whole Time Director, with his due consent, from 16th July, 2019 to 30th September, 2019.

The meeting of the Board of Directors commenced at 11:15 a.m. and closed at 12:55 p.m.

This above is for your information and record please.

Thanking you,

Yours faithfully,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: As above

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Competitive Strategy Leadership Award, India



Business today/YES bank
Excellence Awards-2013



Date: May 1, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

Re: Appointment of Mr. Prashant Gupta as Additional and Independent Director of the Company

Dear Sir/Madam,

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we hereby inform you that the Board of Directors have appointed Mr. Prashant Gupta (DIN: 08122641) as an Additional and Independent Director, with effect from April 30, 2018 for a tenure of 5 years. Enclosed herewith are the brief details of the appointment as prescribed (Annexure A), the content of which is self explanatory.

Thanking You,

Yours faithfully,
For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Annexure A

DETAILS IN TERMS OF REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH SEBI CIRCULAR CIR/CFD/CMD/4/2015 SEPTEMBER 09, 2015 ARE AS UNDER:

Sr. No.	Particulars	Details
1	reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
2	date of appointment/cessation (as applicable) & term of appointment;	April 30, 2018 Appointed as an Additional and Independent Director for a tenure of 5 years
3	brief profile (in case of appointment)	Attached as Annexure B
4	disclosure of relationships between directors (in case of appointment of a director)	NIL

For Eris Lifesciences Limited



Milind Talegaonkar

Company Secretary & Compliance Officer



Shardul Amarchand Mangaldas

CENTURY of EXCELLENCE

PRASHANT GUPTA

Mob + 91 97176 22292

Fax + 91 11 2692 4900

Email prashant.gupta@AMSShardul.com

Annexure-B



Designation | Partner

Practice | Capital Markets

Professional Membership | Bar Council of Delhi, State Bar of California

Education | B.A. (Juris) & M.A. (Juris), University of Oxford, England; B.Com (Hons.); Shri Ram College of Commerce, University of Delhi

Mr. Prashant Gupta is a Partner in the firm's corporate department, focusing primarily on capital markets transactions. He represents both issuers and underwriters in various equity and debt capital raising transactions, including initial public offerings, rights issues and QIP offerings, buy-backs, capital restructurings and pre-IPO private placements. Prashant has been recognized by *Who's Who Legal*, *Chambers Asia*, *Indian Lawyer 250*, *Legal500* and other legal industry publications as one of the leading capital markets practitioners in India. He has also been selected by the *Indian Business Law Journal* as one of the top 100 lawyers in India in 2016 and 2017.

Prashant has advised on capital markets transactions that have raised over US\$30 billion globally. Several of the deals, as well as other transactions he has advised on, have been selected as 'Deals of the Year' by the International Financial Law Review (IFLR) Asia, India Business Law Journal, and the Asian-MENA Counsel Magazine. He has also acted on various international capital markets transactions by India focused companies, including the IPOs in the United States (NASDAQ/NYSE) by *MakeMyTrip Limited*, *Azure Power Global Limited*, *Eros International plc*, and *Videocon d2h*, as well as the reorganization and listing on the NYSE by *Vedanta Limited*. He has also advised on the buyback of shares by *Infosys Limited*, which was amongst the largest buybacks in India.

He has advised the underwriters in the US\$3.4 billion IPO by *Coal India Limited* in 2010, which has been the *largest IPO* in India and acted as sole Indian counsel for the US\$1.7 billion bond offering by *Vedanta Resources*, which has been the largest bond offering by an Indian group.





Shardul Amarchand Mangaldas

CENTURY of EXCELLENCE

Prashant received his Bachelor of Arts in Jurisprudence and Master of Arts in Jurisprudence from the University of Oxford, England, and a Bachelor of Commerce from the Shri Ram College of Commerce, University of Delhi.





EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: February 02, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: CHANGE IN BOARD OF DIRECTORS

Dear Sir/Madam,

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we wish to inform that there is a change in the Board of Directors resulting due to resignation of Mr. Shardul Suresh Shroff, Independent Director of the Company, given on account of his personnel commitments. The Cessation is effective from 1st February, 2018.

Kindly take the above intimation on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: October 06, 2017

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: CHANGE IN BOARD OF DIRECTORS

Dear Sir/Madam,

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we wish to inform that there is a change in the Directors resulting due to resignation of Mr. Rajiv Gulati, Independent Director of the Company. The Cessation is effective from 6th October, 2017.

Kindly take the above intimation on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867